...
search icon
nvs-img

Novartis AG ADR Share Price

NVS
NYQ
$151.04
+$2.36
(1.59%)
1D
Industry: Pharmaceuticals Sector: Health Care

Novartis AG ADR Analyst Forecast

Novartis AG ADR Share Price Chart

Novartis AG ADR Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$285.29B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
20.4542
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.84M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
2.68%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.45
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$97.72 L
$152.48 H
$151.04

About Novartis AG ADR, Common Stock

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. more

Industry: PharmaceuticalsSector: Health Care

Novartis AG ADR Stock Returns

Time FrameNVSSectorS&P500
1-Week Return1.29%-2.13%-0.14%
1-Month Return9.02%-0.5%1.26%
3-Month Return21.94%7.12%1.27%
6-Month Return28.18%16.34%9.67%
1-Year Return43.19%4.95%15.74%
3-Year Return85.38%16.28%66.14%
5-Year Return78.1%33.63%81.39%
10-Year Return138.07%135.85%264.87%

Novartis AG ADR Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue49.90B43.97B43.46B46.66B51.72B[{"date":"2020-12-31","value":96.47,"profit":true},{"date":"2021-12-31","value":85.02,"profit":true},{"date":"2022-12-31","value":84.03,"profit":true},{"date":"2023-12-31","value":90.21,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue15.12B11.73B11.58B12.47B12.83B[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":77.61,"profit":true},{"date":"2022-12-31","value":76.6,"profit":true},{"date":"2023-12-31","value":82.48,"profit":true},{"date":"2024-12-31","value":84.83,"profit":true}]
Gross Profit34.78B32.24B31.88B34.19B38.90B[{"date":"2020-12-31","value":89.41,"profit":true},{"date":"2021-12-31","value":82.89,"profit":true},{"date":"2022-12-31","value":81.96,"profit":true},{"date":"2023-12-31","value":87.9,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin69.70%73.31%73.35%73.27%75.20%[{"date":"2020-12-31","value":92.68,"profit":true},{"date":"2021-12-31","value":97.49,"profit":true},{"date":"2022-12-31","value":97.54,"profit":true},{"date":"2023-12-31","value":97.43,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses24.63B22.18B23.93B24.42B24.35B[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":90.08,"profit":true},{"date":"2022-12-31","value":97.19,"profit":true},{"date":"2023-12-31","value":99.16,"profit":true},{"date":"2024-12-31","value":98.89,"profit":true}]
Operating Income10.15B10.06B7.95B9.77B14.54B[{"date":"2020-12-31","value":69.8,"profit":true},{"date":"2021-12-31","value":69.14,"profit":true},{"date":"2022-12-31","value":54.63,"profit":true},{"date":"2023-12-31","value":67.17,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(1.22B)13.58B(1.40B)(1.14B)(1.51B)[{"date":"2020-12-31","value":-8.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-10.32,"profit":false},{"date":"2023-12-31","value":-8.38,"profit":false},{"date":"2024-12-31","value":-11.13,"profit":false}]
Pre-Tax Income9.88B24.53B7.18B9.12B13.64B[{"date":"2020-12-31","value":40.27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":29.26,"profit":true},{"date":"2023-12-31","value":37.19,"profit":true},{"date":"2024-12-31","value":55.61,"profit":true}]
Income Taxes1.81B1.63B1.13B551.00M1.70B[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.93,"profit":true},{"date":"2022-12-31","value":62.42,"profit":true},{"date":"2023-12-31","value":30.49,"profit":true},{"date":"2024-12-31","value":94.13,"profit":true}]
Income After Taxes8.07B22.91B6.05B8.57B11.94B[{"date":"2020-12-31","value":35.24,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.41,"profit":true},{"date":"2023-12-31","value":37.42,"profit":true},{"date":"2024-12-31","value":52.12,"profit":true}]
Income From Continuous Operations8.07B24.02B6.96B8.15B11.94B[{"date":"2020-12-31","value":33.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":28.96,"profit":true},{"date":"2023-12-31","value":33.95,"profit":true},{"date":"2024-12-31","value":49.71,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income8.07B24.02B6.96B14.85B11.94B[{"date":"2020-12-31","value":33.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":28.95,"profit":true},{"date":"2023-12-31","value":61.82,"profit":true},{"date":"2024-12-31","value":49.71,"profit":true}]
EPS (Diluted)5.786.296.126.817.81[{"date":"2020-12-31","value":74.01,"profit":true},{"date":"2021-12-31","value":80.54,"profit":true},{"date":"2022-12-31","value":78.36,"profit":true},{"date":"2023-12-31","value":87.2,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]

Novartis AG ADR Ratios

Novartis AG ADR Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

NVS
Cash Ratio 0.30
Current Ratio 0.88
Quick Ratio 0.68

Novartis AG ADR Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

NVS
ROA (LTM) 12.13%
ROE (LTM) 32.62%

Novartis AG ADR Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

NVS
Debt Ratio Lower is generally better. Negative is bad. 0.58
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.41

Novartis AG ADR Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

NVS
Trailing PE 20.45
Forward PE 16.23
P/S (TTM) 5.09
P/B 6.45
Price/FCF 50
EV/R 5.47
EV/Ebitda 13.45
PEG 1.21

FAQs

What is Novartis AG ADR share price today?

Novartis AG ADR (NVS) share price today is $151.04

Can Indians buy Novartis AG ADR shares?

Yes, Indians can buy shares of Novartis AG ADR (NVS) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Novartis AG ADR be purchased?

Yes, you can purchase fractional shares of Novartis AG ADR (NVS) via the Vested app. You can start investing in Novartis AG ADR (NVS) with a minimum investment of $1.

How to invest in Novartis AG ADR shares from India?

You can invest in shares of Novartis AG ADR (NVS) via Vested in three simple steps:

  • Click on Sign Up or Invest in NVS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Novartis AG ADR shares
What is Novartis AG ADR 52-week high and low stock price?

The 52-week high price of Novartis AG ADR (NVS) is $152.48. The 52-week low price of Novartis AG ADR (NVS) is $97.72.

What is Novartis AG ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Novartis AG ADR (NVS) is 20.4542

What is Novartis AG ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Novartis AG ADR (NVS) is 6.45

What is Novartis AG ADR dividend yield?

The dividend yield of Novartis AG ADR (NVS) is 2.68%

What is the Market Cap of Novartis AG ADR?

The market capitalization of Novartis AG ADR (NVS) is $285.29B

What is Novartis AG ADR's stock symbol?

The stock symbol (or ticker) of Novartis AG ADR is NVS

How Can Investors Use Novartis AG ADR Share Price Data for Long-Term Investment Decisions?

Consider the share price of Novartis AG ADR as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Novartis AG ADR has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Novartis AG ADR shares for Indian investors?

When investing in Novartis AG ADR shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Novartis AG ADR stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Novartis AG ADR share price with other stocks in the same sector?

Rather than merely checking the share price of Novartis AG ADR and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Novartis AG ADR stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top